Your browser doesn't support javascript.
loading
Cost utility of vitamin D supplementation in adults with mild to moderate asthma.
Antonio Buendía, Jefferson; Rodriguez-Martinez, Carlos E; Sossa-Briceño, Monica P.
Afiliação
  • Antonio Buendía J; Research group in Pharmacology and Toxicology "INFARTO", Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia.
  • Rodriguez-Martinez CE; Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.
  • Sossa-Briceño MP; Department of Pediatric Pulmonology, School of Medicine, Universidad El Bosque, Bogota, Colombia.
J Asthma ; 60(5): 951-959, 2023 05.
Article em En | MEDLINE | ID: mdl-35920247
OBJECTIVE: Uncontrolled asthma significantly impairs health-related quality of life and work productivity. Some add-on therapies, such as vitamin D supplements, safely reduce the rate of asthma exacerbation. The purpose of this study was to assess the cost-utility of vitamin D supplementation in adults with mild to moderate persistent asthma in Colombia. METHODS: A Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with severe asthma in Colombia. Total costs and QALYs of two therapy strategies, vitamin D supplementation plus ICS versus ICS alone, were calculated over a one-year time horizon. Deterministic and probability sensitivity analyses were conducted, and cost-effectiveness was evaluated at a willingness-to-pay value of $5,180 per QALY gained. RESULTS: The base-case analysis showed that compared with no supplementation, vitamin D supplementation was associated with higher costs and higher QALYs. The expected annual cost per patient with vitamin D supplementation was US$1338 and without this supplementation it was US$1095. The QALYs per person estimated with vitamin D supplementation was 0.80, and without this supplementation it was 0.63. The estimated incremental cost-effectiveness ratio (ICER) was US$1583 per QALY. CONCLUSIONS: Add-on vitamin D supplement was cost-effective when added to the usual care in patients with mild to moderate persistent asthma. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Adult / Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Adult / Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido